Skip to main content

International research team at Mahidol University in Bangkok has developed a new blood test capable of detecting clinically significant prostate cancer in high-risk patients.

An international research team at Mahidol University in Bangkok has developed a new blood test capable of detecting clinically significant prostate cancer in high-risk patients. According to lead scientist, Dr Sebastian Bhakdi, the test is capable of isolating and visualizing tumor-associated circulating endothelial cells (tCEC) from a small blood sample.
The tCEC cells are believed to derive from a tumor's blood vessels, making them highly promising biomarkers for the detection of early-stage cancers. Unfortunately, they are extremely rare and almost indiscernible from normal blood cells. The new test is the world's first tCEC-based screening assay capable of routinely detecting tCEC cells in standard blood samples.
Dr. Bhakdi further explained that not all cancers need treatment. Testing for tCEC cells not only helps to detect cancer in its early-stage, but can also determine whether or not the disease present is aggressive in nature. Furthermore, the new test will not act as stand-alone assessment, but as an add-on to prostate-specific antigen (PSA) screening that would fit into existing diagnostic pathways.

 

Share this article

thailandtoday thailandtoday thailandtoday

thailandtoday thailandtoday thailandtoday

thailandtoday thailandtoday thailandtoday

thailandtoday thailandtoday thailandtoday

thailandtoday thailandtoday thailandtoday

thailandtoday thailandtoday thailandtoday

thailandtoday thailandtoday thailandtoday